This article was originally published in The Gray Sheet
Withdraws a proposed public offering registered on Feb. 9 with the Securities and Exchange Commission ("The Gray Sheet" Feb. 15, p. 13). Lynda S. Dreiling, executive vice president, says in a March 16 announcement that the firm's decision is "based on current market conditions for the securities of health care companies, and the recent decline in the market price of Staodyn common stock." The withdrawal comes five days after Staodyn announced a restructuring of the offering and a plan to extend the term of warrants due to expire in June and to reduce their exercise price. As a result of the canceled offering, Staodyn says it will not reduce the exercise price of the warrants and may not extend their term.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.